APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive: In terms of a comparison between this paper and our previous paper [21], there are distinct differences between the two; in the current study: (1) the target protein for protection against CML toxicity is lipid-free apoA-I; (2) there is a comparison of embryo survivability among monoclonal antibodies, Infliximab, Etanercept, and Tocilizumab; (3) there is a comparison of adult zebrafish survivability in a hyperlipidemic state with a higher dose of CML (final 6 mM).